Esperion touts CLEAR result while investors see uncertainty

6 March 2023

While Esperion (Nasdaq: ESPR) announced a statistically-significant outcome for heart med Nexletol (bempedoic acid) over the weekend, markets were less than impressed with the size of the treatment benefit.

Ahead of the opening bell in New York on Monday, shares in the Michigan, USA-based company were down by around a fifth.

Full results from the CLEAR trial were published in the New England Journal of Medicine (NEJM) and presented at the American College of Cardiology’s Annual Scientific Session & Expo.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK